The mutation frequency of TP53 (61% versus 44%, respectively; OR, 2.029; P < 0.01), TTN (54% versus 39%, respectively; OR, 1.84; P < 0.05), ZFHX4 (41% versus 26%, respectively; OR, 2.021; P < 0.01), XIRP2 (37% versus 19%, respectively; OR, 2.552; P < 0.01), KEAP1 (31% versus 15%, respectively; OR, 2.598; P < 0.01) and COL11A1 (29% versus 16%, respectively; OR, 2.037; P < 0.01) was higher in the high-ARS group, suggesting that angiogenesis relates to the occurrence of somatic mutations in tumor cells (Figure 6G). Here, TP53 is linked to neoplasm.